Novavax, Inc. (Nasdaq: NVAX) announced complete target enrollment of the pivotal Phase 3 clinical trial, known as Resolve™, of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE